Goldfinch Bio CEO Tony Johnson (L) and Karuna Therapeutics CEO Bill Meury

Karuna li­cens­es Goldfinch as­sets to com­pete with Boehringer In­gel­heim in neu­ro­science

Karuna Ther­a­peu­tics is look­ing to com­pete with Boehringer In­gel­heim on de­pres­sion and anx­i­ety with a new li­cense to Goldfinch Bio’s as­sets …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.